<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: <z:chebi fb="105" ids="17234">Glucose</z:chebi>-6-phosphate dehydrogenase (G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) deficiency is frequently associated with <z:hpo ids='HP_0003265'>neonatal hyperbilirubinemia</z:hpo>, which in severe cases may cause <z:hpo ids='HP_0001343'>kernicterus</z:hpo> and <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Because G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient individuals frequently undergo <z:hpo ids='HP_0011009'>acute</z:hpo>, trigger-induced hemolytic episodes, <z:hpo ids='HP_0001878'>increased hemolysis</z:hpo> has frequently been implied in the pathogenesis of this <z:hpo ids='HP_0003265'>neonatal hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, in Sephardic Jewish G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient neonates, the rate of <z:mp ids='MP_0010163'>hemolysis</z:mp>, reflected by blood carboxyhemoglobin values corrected for inspired <z:chebi fb="168" ids="17245">carbon monoxide</z:chebi>, has been shown to be elevated, not only in those who developed <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, but also, to a similar extent, in those who remained only moderately jaundiced </plain></SENT>
<SENT sid="3" pm="."><plain>Because at any point, serum total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> values reflect a balance between <z:chebi fb="0" ids="16990">bilirubin</z:chebi> production on the one hand and <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugation and elimination on the other, we suspected <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugation to be a key factor in the pathogenesis of the <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Physiologically, a fraction of conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> refluxes from the hepatocyte to the serum, and accurate determination of serum conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> fractions can be used to mirror intrahepatocytic <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Using this principle, we previously demonstrated a decreased diconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> fraction in hyperbilirubinemic G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient neonates compared with hyperbilirubinemic G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-<z:mpath ids='MPATH_458'>normal</z:mpath> controls, suggesting diminished <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugation </plain></SENT>
<SENT sid="6" pm="."><plain>This conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> pattern probably reflects the recently described interaction between <z:e sem="disease" ids="C0017758" disease_type="Disease or Syndrome" abbrv="">G-6-PD deficiency</z:e> and the variant promoter for the gene encoding the <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugating enzyme <z:chebi fb="15" ids="17659">UDP</z:chebi> glucuronosyltransferase, as seen in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, we postulated that efficiency of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugation is a crucial factor in the development of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient neonates </plain></SENT>
<SENT sid="8" pm="."><plain>We hypothesized that those G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient neonates who develop <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> would have decreased <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugation ability, whereas those with a more efficient conjugating system would have a lesser degree of <z:e sem="disease" ids="C0020433" disease_type="Disease or Syndrome" abbrv="">bilirubinemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>METHODS: Term, healthy, male, G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient neonates with no other obvious predisposing cause for <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> were selected at random when their serum <z:chebi fb="1" ids="30105">diazo</z:chebi> total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> values ranged from 171 to 254 micromol/L (10-14.9 mg/dL) </plain></SENT>
<SENT sid="10" pm="."><plain>At this point, simultaneous with the <z:chebi fb="1" ids="30105">diazo</z:chebi> <z:chebi fb="0" ids="16990">bilirubin</z:chebi> determination, serum was collected and frozen for high-performance liquid chromatography (HPLC) measurement of serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> fractions </plain></SENT>
<SENT sid="11" pm="."><plain>The infants were followed clinically and with serum <z:chebi fb="1" ids="30105">diazo</z:chebi> <z:chebi fb="0" ids="16990">bilirubin</z:chebi> determinations until they either did not exceed a serum <z:chebi fb="1" ids="30105">diazo</z:chebi> <z:chebi fb="0" ids="16990">bilirubin</z:chebi> value of 254 micromol/L (14.9 mg/dL) (nonhyperbilirubinemic) or until <z:chebi fb="0" ids="16990">bilirubin</z:chebi> values rose above this level (hyperbilirubinemic), by a process of self-selection </plain></SENT>
<SENT sid="12" pm="."><plain>A method of alkaline methanolysis, followed by reverse-phase HPLC, was used to measure unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and the mono- and diconjugated fractions of serum conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Total HPLC <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and total conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> values were calculated from these measured <z:chebi fb="0" ids="16990">bilirubin</z:chebi> fractions </plain></SENT>
<SENT sid="14" pm="."><plain>Patients also were classified according to the serum total conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> value as low <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugators (serum total conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> less than median) or as high <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugators (serum total conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> greater than median) </plain></SENT>
<SENT sid="15" pm="."><plain>The data were analyzed by comparing serum conjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> fractions between the hyperbilirubinemic and nonhyperbilirubinemic groups and the risk of developing <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in the low <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugators, relative to that of the high <z:chebi fb="0" ids="16990">bilirubin</z:chebi> conjugators </plain></SENT>
<SENT sid="16" pm="."><plain>RESULTS: Neonates were sampled at 53 +/- 12 and 58 +/- 12 hours for the subsequently hyperbilirubinemic and nonhyperbilirubinemic groups, respectively (NS) </plain></SENT>
<SENT sid="17" pm="."><plain>Initial (ie, at the time of sampling) serum total <z:chebi fb="1" ids="30105">diazo</z:chebi> <z:chebi fb="0" ids="16990">bilirubin</z:chebi> values (mean +/- SD) were almost identical for the subsequently hyperbilirubinemic and nonhyperbilirubinemic groups (214 +/ </plain></SENT>
</text></document>